EVOK 5.48 Evoke Pharma, Inc.
| Range: | 3.54-17.88 | Vol Avg: | 73325 | Last Div: | 0 | Changes: | 0.19 |
| Beta: | 0.39 | Cap: | 0.00B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Wed Sep 25 2013 | Empoloyees: | 4 | ||
| CUSIP: | 30049G104 | CIK: | 0001403708 | ISIN: | US30049G2030 | Country: | US |
| CEO: | Mr. Matthew J. D'Onofrio MBA | Website: | https://www.evokepharma.com | ||||
Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow